Claudine Isaacs
researcher (ORCID 0000-0002-9646-1260)
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11.Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project resultsAuthor Correction: Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis.BRCA1/2 mutations and triple negative breast cancersBreast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response EndpointEvaluation and management of women with BRCA1/2 mutations.Extended Adjuvant Endocrine Therapy for Postmenopausal Women: Treating Many to Benefit a Few.Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation CarriersGenetic testing for hereditary breast and ovarian cancer and the USPSTF recommendationsGenome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.Hot flushesHow Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing.Management of women at increased risk for hereditary breast cancer.Management updates for women with a BRCA1 or BRCA2 mutationNo clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.Practical aspects of delivering hereditary cancer risk counselingPublisher Correction: Shared heritability and functional enrichment across six solid cancersTreatment of primary breast tumors in de novo metastatic breast cancerUtilizing prognostic and predictive factors in breast cancer
author
Claudine Isaacs
researcher (ORCID 0000-0002-9646-1260)
worksFor
type
comment
researcher (ORCID 0000-0002-9646-1260)
@en
wetenschapper
@nl
label
Claudine Isaacs
@en
Claudine Isaacs
@nl